Jump to content

Draft:James N. Kochenderfer, M.D.

From Wikipedia, the free encyclopedia
  • Comment: The 1st para of the 'Education and early career' section is entirely unreferenced. DoubleGrazing (talk) 09:24, 26 December 2024 (UTC)

James N. Kochenderfer is an American physician-scientist. He is currently a Senior Investigator at the National Cancer Institute, National Institutes of Health, Bethesda, Maryland.[1]

Education and early career

[edit]

James Kochenderfer earned and bachelor's degree in chemistry and a M.D. at West Virginia University.[2] He completed an Internal Medicine residency at Vanderbilt University followed by an Oncology Fellowship at the University of Texas M.D. Anderson Cancer Center in Houston, Texas. He completed a Hematology Fellowship at Baylor College of Medicine in Houston, Texas. He then undertook an extensive period of post-doctoral training in cancer vaccines and adoptive T-cell therapy at the National Cancer Institute.[3] This training was conducted in the laboratories of Dr. Ronald E. Gress and Dr. Steven A. Rosenberg. Following these fellowships, Dr. Kochenderfer held positions as an Assistant Clinical Investigator and then an Investigator at the National Cancer Institute. In 2020, Dr. Kochenderfer was granted tenure and assumed his current position of Senior Investigator.[4]

Dr. Kochenderfer is an investigator and author in the field of chimeric antigen receptor (CAR) T-cell therapies for cancer.[5][6] Dr. Kochenderfer's research has focused on developing new CAR T-cell therapies for hematologic malignancies such as leukemia, lymphoma, and multiple myeloma.[7][8][9] Dr. Kochenderfer was the lead author of the first paper to report antigen-specific activity of CAR T cells targeting CD19.[10] Dr. Kochenderfer and coworkers conducted early studies that demonstrated the effectiveness of anti-CD19 CAR T cells against lymphoma.[11] CAR T cells targeting CD19 have gone on to become important U.S. Food and Drug Administration (FDA)-approved treatments for lymphoma and leukemia.[12] Dr. Kochenderfer and coworkers were also the first to report CAR T cells targeting B-cell maturation antigen.[13] CAR T cells targeting BCMA are an important FDA-approved treatment for multiple myeloma.[14] Dr. Kochenderfer contributed to early development of the first FDA-approved CAR T-cell therapy for multiple myeloma.[15][16]

Selected publications

[edit]

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102. 10.1182/blood-2010-04-281931.[17]

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology 33, 540-549. 10.1200/JCO.2014.56.2025.[18]

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research 19, 2048-2060. 10.1158/1078-0432.CCR-12-2422.[19]

T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688-1700. 10.1182/blood-2016-04-711903.[20]

Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. New England Journal of Medicine 380, 1726-1737. 10.1056/NEJMoa1817226.[21]

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nature Medicine 26, 270-280. 10.1038/s41591-019-0737-3.[22]

Selected awards

[edit]
  • American Society of Gene and Cell Therapy Outstanding New Investigator Award, 2017[23]
  • Foundation of the National Institutes of Health Trailblazer Award, 2019.[24]
  • Elected member of the American Society for Clinical Investigation, 2020.[25]
  • Top 10 Clinical Research Achievement Award, 2020.[26]
  • NIH Director’s Award, 2020.[27]

References

[edit]
  1. ^ "James Kochenderfer, NCI website". James Kochenderfer, NCI website. National Institutes of Health.
  2. ^ "Biograpy NCI website". NCI James Kochenderfer. National Institutes of Health.
  3. ^ "NCI Biography". NCI Biography James Kochenderfer. National Institutes of Health United States.
  4. ^ NCI Website James Kochenderfer. National Institutes of Health https://ccr.cancer.gov/staff-directory/james-n-kochenderfer#research. {{cite web}}: Missing or empty |title= (help)
  5. ^ "American Society for Clinical Investigation Membership". American Society for Clinical Investigation. ASCI.
  6. ^ "Google Scholar page James Kochenderfer". Google Scholar.
  7. ^ "JCO Exclusive: Genetically Engineered Cells Brings About Complete Response in Lymphoma". Asco Connection. American Society of Clinical Oncology.
  8. ^ Cappell, K. M.; Sherry, R. M.; Yang, J. C.; Goff, S. L.; Vanasse, D. A.; McIntyre, L.; Rosenberg, S. A.; Kochenderfer, J. N. (2020). "Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 38 (32). National Library of Medicine: 3805–3815. doi:10.1200/JCO.20.01467. PMC 7655016. PMID 33021872.
  9. ^ "The status of anti-BCMA CAR T-cell therapy in multiple myeloma. An interview with Dr James Kochenderfer". MultipleMyelomaHub.
  10. ^ Kochenderfer, J. N.; Wilson, W. H.; Janik, J. E.; Dudley, M. E.; Stetler-Stevenson, M.; Feldman, S. A.; Maric, I.; Raffeld, M.; Nathan, D. A.; Lanier, B. J.; Morgan, R. A.; Rosenberg, S. A. (2010). "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19". Blood. 116 (20). National Library of Medicine: 4099–4102. doi:10.1182/blood-2010-04-281931. PMC 2993617. PMID 20668228.
  11. ^ Kochenderfer, J. N.; Dudley, M. E.; Kassim, S. H.; Somerville, R. P.; Carpenter, R. O.; Stetler-Stevenson, M.; Yang, J. C.; Phan, G. Q.; Hughes, M. S.; Sherry, R. M.; Raffeld, M.; Feldman, S.; Lu, L.; Li, Y. F.; Ngo, L. T.; Goy, A.; Feldman, T.; Spaner, D. E.; Wang, M. L.; Chen, C. C.; Kranick, S. M.; Nath, A.; Nathan, D. A.; Morton, K. E.; Toomey, M. A.; Rosenberg, S. A. (2015). "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33 (6). National Library of Medicine: 540–549. doi:10.1200/JCO.2014.56.2025. PMC 4322257. PMID 25154820.
  12. ^ "FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma". U.S. Food and Drug Administration. 24 March 2020.
  13. ^ Carpenter, R. O.; Evbuomwan, M. O.; Pittaluga, S.; Rose, J. J.; Raffeld, M.; Yang, S.; Gress, R. E.; Hakim, F. T.; Kochenderfer, J. N. (2013). "B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma". Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 19 (8). National Library of Medicine: 2048–2060. doi:10.1158/1078-0432.CCR-12-2422. PMC 3630268. PMID 23344265.
  14. ^ Mikkilineni, Lekha; Kochenderfer, James N. (2021). "CAR T cell therapies for patients with multiple myeloma". Nature Reviews Clinical Oncology. 18 (2). Nature: 71–84. doi:10.1038/s41571-020-0427-6. PMID 32978608.
  15. ^ Raje, N.; Berdeja, J.; Lin, Y.; Siegel, D.; Jagannath, S.; Madduri, D.; Liedtke, M.; Rosenblatt, J.; Maus, M. V.; Turka, A.; Lam, L. P.; Morgan, R. A.; Friedman, K.; Massaro, M.; Wang, J.; Russotti, G.; Yang, Z.; Campbell, T.; Hege, K.; Petrocca, F.; Quigley, M. T.; Munshi, N.; Kochenderfer, J. N. (2019). "Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma". The New England Journal of Medicine. 380 (18). National Library of Medicine: 1726–1737. doi:10.1056/NEJMoa1817226. PMC 8202968. PMID 31042825.
  16. ^ "FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma". U.S. Food and Drug Administration. 9 August 2024.
  17. ^ Kochenderfer, J. N.; Wilson, W. H.; Janik, J. E.; Dudley, M. E.; Stetler-Stevenson, M.; Feldman, S. A.; Maric, I.; Raffeld, M.; Nathan, D. A.; Lanier, B. J.; Morgan, R. A.; Rosenberg, S. A. (2010). "Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19". Blood. 116 (20). National Library of Medicine: 4099–4102. doi:10.1182/blood-2010-04-281931. PMC 2993617. PMID 20668228.
  18. ^ Kochenderfer, J. N.; Dudley, M. E.; Kassim, S. H.; Somerville, R. P.; Carpenter, R. O.; Stetler-Stevenson, M.; Yang, J. C.; Phan, G. Q.; Hughes, M. S.; Sherry, R. M.; Raffeld, M.; Feldman, S.; Lu, L.; Li, Y. F.; Ngo, L. T.; Goy, A.; Feldman, T.; Spaner, D. E.; Wang, M. L.; Chen, C. C.; Kranick, S. M.; Nath, A.; Nathan, D. A.; Morton, K. E.; Toomey, M. A.; Rosenberg, S. A. (2015). "Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor". Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33 (6). National Library of Medicine: 540–549. doi:10.1200/JCO.2014.56.2025. PMC 4322257. PMID 25154820.
  19. ^ Carpenter, R. O.; Evbuomwan, M. O.; Pittaluga, S.; Rose, J. J.; Raffeld, M.; Yang, S.; Gress, R. E.; Hakim, F. T.; Kochenderfer, J. N. (2013). "B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma". Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 19 (8). National Library of Medicine: 2048–2060. doi:10.1158/1078-0432.CCR-12-2422. PMC 3630268. PMID 23344265.
  20. ^ Ali, S. A.; Shi, V.; Maric, I.; Wang, M.; Stroncek, D. F.; Rose, J. J.; Brudno, J. N.; Stetler-Stevenson, M.; Feldman, S. A.; Hansen, B. G.; Fellowes, V. S.; Hakim, F. T.; Gress, R. E.; Kochenderfer, J. N. (2016). "T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma". Blood. 128 (13). National Library of Medicine: 1688–2300. doi:10.1182/blood-2016-04-711903. PMC 5043125. PMID 27412889.
  21. ^ Raje, Noopur; Berdeja, Jesus; Lin, Yi; Siegel, David; Jagannath, Sundar; Madduri, Deepu; Liedtke, Michaela; Rosenblatt, Jacalyn; Maus, Marcela V.; Turka, Ashley; Lam, Lyh-Ping; Morgan, Richard A.; Friedman, Kevin; Massaro, Monica; Wang, Julie; Russotti, Greg; Yang, Zhihong; Campbell, Timothy; Hege, Kristen; Petrocca, Fabio; Quigley, M. Travis; Munshi, Nikhil; Kochenderfer, James N. (2019). "Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma". New England Journal of Medicine. 380 (18): 1726–1737. doi:10.1056/NEJMoa1817226. PMID 31042825.
  22. ^ Brudno, J. N.; Lam, N.; Vanasse, D.; Shen, Y. W.; Rose, J. J.; Rossi, J.; Xue, A.; Bot, A.; Scholler, N.; Mikkilineni, L.; Roschewski, M.; Dean, R.; Cachau, R.; Youkharibache, P.; Patel, R.; Hansen, B.; Stroncek, D. F.; Rosenberg, S. A.; Gress, R. E.; Kochenderfer, J. N. (2020). "Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma". Nature Medicine. 26 (2). National Library of Medicine: 270–280. doi:10.1038/s41591-019-0737-3. PMC 7781235. PMID 31959992.
  23. ^ "American Society of Gene and Cell Therapy Outstanding New Investigator Award". American Society of Gene and Cell Therapy.
  24. ^ "Trailblazer Award". Foundation for the National Institutes of Health. 24 October 2019.
  25. ^ "American Society for Clinical Investigation membership". American Society for Clinical Investigation. ASCI.
  26. ^ "Top 10 Clinical Research Award". Clinical Research Forum.
  27. ^ "2020 NIH Director's Awards". National Institutes of Health.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:James_N._Kochenderfer,_M.D.&oldid=1265468140"